BACKGROUND: Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer's dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons tonaproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments were terminated. During the treatment interval, 32 cases of AD revealed increased rates in both NSAID-assigned groups. METHODS: We continued the double-masked ADAPT protocol for 2 additional years to investigate incidence of AD (primary outcome). We then collected cerebrospinal fluid (CSF) from 117 volunteer participants to assess their ratio of CSF tau to Aβ(1-42.) RESULTS: Including 40 new events observed during follow-up of 2,071 randomized individuals (92% of participants at treatment cessation), there were 72 AD cases. Overall, NSAID-related harm was no longer evident, but secondary analyses showed that increased risk remained notable in the first 2.5 years of observations, especially in 54 persons enrolled with cognitive impairment--no dementia (CIND). These same analyses showed later reduction in AD incidence among asymptomatic enrollees who were given naproxen. CSF biomarker assays suggested that the latter result reflected reduced Alzheimer-type neurodegeneration. CONCLUSIONS: These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years. Thus, treatment effects differ at various stages of disease. This hypothesis is consistent with data from both trials and epidemiological studies.
RCT Entities:
BACKGROUND: Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer's dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments were terminated. During the treatment interval, 32 cases of AD revealed increased rates in both NSAID-assigned groups. METHODS: We continued the double-masked ADAPT protocol for 2 additional years to investigate incidence of AD (primary outcome). We then collected cerebrospinal fluid (CSF) from 117 volunteer participants to assess their ratio of CSF tau to Aβ(1-42.) RESULTS: Including 40 new events observed during follow-up of 2,071 randomized individuals (92% of participants at treatment cessation), there were 72 AD cases. Overall, NSAID-related harm was no longer evident, but secondary analyses showed that increased risk remained notable in the first 2.5 years of observations, especially in 54 persons enrolled with cognitive impairment--no dementia (CIND). These same analyses showed later reduction in AD incidence among asymptomatic enrollees who were given naproxen. CSF biomarker assays suggested that the latter result reflected reduced Alzheimer-type neurodegeneration. CONCLUSIONS: These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years. Thus, treatment effects differ at various stages of disease. This hypothesis is consistent with data from both trials and epidemiological studies.
Authors: Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan Journal: Arch Neurol Date: 2008-05-12
Authors: Joshua A Sonnen; John C Breitner; Mark A Lovell; William R Markesbery; Joseph F Quinn; Thomas J Montine Journal: Free Radic Biol Med Date: 2008-04-24 Impact factor: 7.376
Authors: C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh Journal: Neurology Date: 2007-04-25 Impact factor: 9.910
Authors: Harald Hampel; Katharina Bürger; Stefan J Teipel; Arun L W Bokde; Henrik Zetterberg; Kaj Blennow Journal: Alzheimers Dement Date: 2007-12-21 Impact factor: 21.566
Authors: Nathaniel S Woodling; Damien Colas; Qian Wang; Paras Minhas; Maharshi Panchal; Xibin Liang; Siddhita D Mhatre; Holden Brown; Novie Ko; Irene Zagol-Ikapitte; Marieke van der Hart; Taline V Khroyan; Bayarsaikhan Chuluun; Prachi G Priyam; Ginger L Milne; Arash Rassoulpour; Olivier Boutaud; Amy B Manning-Boğ; H Craig Heller; Katrin I Andreasson Journal: Brain Date: 2016-05-13 Impact factor: 13.501